February 5, 2024

NRG Oncology Broadcast archives are accessible from our website at any time. Please bookmark this link for your convenience.

Please see the additional information added under the Protocol Activity section for NRG-GU012 Amendment 4.

Pre-Register for the NRG Oncology 2024 Winter Meeting!

The NRG Winter Meeting will be held in-person only at the World Center Marriott in Orlando, FL from Thursday, February 15, 2024 - Saturday, February 17, 2024 with select virtual session offerings. Please visit our meeting webpage for the agenda and more information. Register here

Winter Symposium - IDEA: Inclusion, Diversity, Equity and Access of Underrepresented Patients to Clinical Trials

Register here for the Winter 2024 Educational Symposium on Thursday, February 15, 2024 from 8am-12pm ET. The symposium will include noted Oncologists and Scientists serving as speakers and moderators. The speakers will focus their presentations on providing a framework for the barriers and solutions to increasing IDEA (Inclusion, Diversity, Equity, and Access) of underrepresented patients to clinical trials. Read more

NRG Oncology Particle Therapy Working Group Symposium

The NRG Oncology Particle Therapy Working Group Symposium is being held on Friday, February 16, 2024 from 10:15-10:50 am ET. The theme is “Overcoming Obstacles to Enrollment on Proton Therapy NRG Oncology Trials” and will be moderated by Charles B. Simone II, MD. The following talks are planned: Patient barriers: Engaging patients and enhancing their willingness to participate, presented by Kristin Higgins, MD; Provider barriers: Patient selection and enrollment equipoise, presented by Steven Lin, MD; and Enrollment challenges: Addressing insurance obstacles and designing pragmatic clinical trials, presented by Nancy Mendenhall, MD.

The Role of Spatial Biology in Oncology at #NRG2024

The NRG Translational Science Committee will be hosting their session “The Role of Spatial Biology in Oncology: Opportunities and Challenges for Translational Research” on Thursday, February 15, 2024 from 3-5pm at the upcoming NRG Meeting in Orlando. Presentations include the 3D spatial biology of archived FFPE tissue, new insights and opportunities in spatial biology, the multiplexed tissue imaging for biomarker and translational science discovery, and whole slide imaging mass cytometry for rapid profiling of tumor spatial heterogeneity and immune microenvironments. View the session flyer here. Register here. Click here to view the session flyer.

NRG Oncology Protocol Support Committee – Educational Sessions

Please be sure to sign up to attend the PSC Nurse/CRP Sessions being held during the NRG Oncology Winter Meeting in Orlando. The Protocol Support Committee (PSC) will offer Introduction to Clinical Trials: Principles of NRG Oncology Clinical Trial Management for Nurse/CRPs on Thursday, February 15; and Continuing Education Session for Nurse/CRPs on Friday, February 16. These sessions will be held virtually and in-person and are for both seasoned and new research staff. Please refer to the posted flyers and agendas (login required) for more details about the PSC programing offered at #NRG2024.

The PSC is thrilled to announce that the PSC sessions have been approved by the Virginia Nurses Association to award contact hours. The Virginia Nurses Association is accredited as an approver of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

#NRG2024 Social Media Workshop – Virtual Session

The NRG Oncology Communications Committee is pleased to announce our Social Media Workshop as part of #NRG2024. The workshop, being held as a virtual session, is scheduled for Monday, February 12, from 4-5pm EST. Drs. Kristin Higgins and Miriam Knoll, members of the NRG Oncology Communications Committee, are the workshop chairs. The session speakers include Kristen Kimball, advocate for lung cancer awareness and retired physiology instructor from Boston; and Dr. Lucinda Morris, a radiation oncologist and co-chair of the Targeting Cancer initiative, from Sydney, Australia. Please see the session flyer for details. Register here for the session.

ACTIVATIONS

1. BRAIN

NRG-BN010: Re-Activation with Protocol Amendment 3. Based on the study’s safety run-in results, Dose Level 3 (tocilizumab 8 mg/kg + atezolizumab 1680 mg every 4 weeks) is moving forward into the phase II design. See Study Memorandum dated February 1, 2024 (posted on CTSU).

2. CANCER CONTROL & SYMPTOM MANAGEMENT

NRG-CC011: Activation Date: February 2, 2024 (posted on CTSU).

AMENDMENT

GENITOURINARY

NRG-GU012: Amendment 4, version dated January 03, 2024, posted on CTSU.



OTHER PROTOCOL NOTICES

1. ALL DISEASE SITES

NRG-GY022: Reminder: Actively Recruiting MALE Patients only Read More

2. BIOSPECIMEN BANK

Printing Biospecimen Transmittal PDFs from Rave

Please note an effort is underway to clarify how to obtain a Biospecimen Transmittal PDF for submission to the NRG Oncology Biospecimen Bank. Read More

3. CANCER CONTROL & PREVENTION

NRG-CC010: The study is now open to NRG sites in Japan and South Korea. The optional biospecimen collection does not apply to sites participating in these countries.

4. GASTROINTESTINAL

NRG-GI008/CIRCULATE-NORTH AMERICA: Important reminders for submitting blood and tissue specimens to Natera for central ctDNA testing (memo posted on CTSU).

5. GENITOURINARY

NRG-GU011: Reminder! This phase II trial for patients with Oligometastatic Prostate Cancer is open to enrollment. The study is open to all NCTN member sites in the U.S and Canada. Please help us enroll. Protocol documents are posted on the CTSU website.

NRG-GU013: The following documents are posted to the CIRB portion of the CTSU website:

• Consent Form with corrected page number plus CIRB note to file
• Patient History Form (including instructions)

6. GYNECOLOGIC

EAY191-N4: Appendix XI, Section II, 1^st bullet: Reports should be REDACTED. Section 10.2: Footnote 2 will be deleted. These changes will be made with the next amendment.

GOG-0210: Reminder: Biospecimens, biomarker data, clinical data, and epidemiologic data are available for request. Please visit the NRG Oncology website for more information on this important study with the overall goal of improving the outcome and/or quality of life for patients with endometrial cancer.

NRG-GY031: Please note, there is an error in the section 4.2 table and the Biospecimen Collection and Submission Manual. The Part I PK collection is to be done on Cycle 1, Day 1, and Cycle 1, Day 8. This will be updated with the next amendment.

7. HEAD & NECK

NRG-HN008

Reminder: please update treatment and AE data weekly. This is a Phase I trial and timely data submission is very important.

8. VTOC TRAINING

The VTOC Webinar Training Series schedule and registration is available for NRG Oncology Research Associates working on RTOG 0924, RTOG 0920, NRG-HN001, NRG-HN002, NRG-CC003, NRG-CC005, NRG-BR009, NRG-CC011, and NRG/SWOG S1914. Space is limited so register now and reserve your seat. The next webinar training is scheduled for Wednesday, February 21, 2024.

NRG Oncology Selects Health Equity Fellows for 2024

NRG Oncology (NRG), a National Cancer Institute (NCI) National Clinical Trials Network (NCTN) group, recently announced that they have named two health equity fellows as a part of the organization’s Health Equity Fellowship Program. Fellowship awardees include Dr. Onyinye Balogun and Dr. Stephanie Rieder. Read more

Statistical Reports Now Available

The February 2024 Statistical Reports for active studies are now available on the NRG Oncology website. Please note that you will need to log in with your CTEP credentials to access the study reports. Click here to access the February 2024 Statistical Reports.

NRG Oncology Confidential Member Survey

Please read our survey FAQ’s. All NRG Members should have received an email from the University of Chicago’s Survey Lab <noreply@qemailserver.com> containing a unique survey link. If you have not already completed the survey, please check your inbox and possibly your spam/junk mailbox for the email so that you can help us collect this important information. Please send any additional questions to nrg-broadcasts@nrgoncology.org.

NRG is Accepting Applications for Vice Chair, Radiation Oncology Committee

Deadline: March 1, 2024

We are seeking nominations for the position of Vice Chair, NRG Oncology Radiation Oncology Committee. The Radiation Oncology Committee within NRG Oncology coordinates the group's radiation oncology-related activities.



The successful candidate has expertise in brachytherapy, radiation therapy clinical trial protocol development and a track record of developing short- and long-term strategic plans to address the research interests of the radiation oncology community. Candidates should demonstrate a history of mentorship and a willingness to provide timely collaboration with members and liaisons of the various NRG committees and staff, as well as with other professional societies, and to address common concerns in support of NRG’s mission and scientific focus. More information and how to apply

NRG Oncology is pleased to report the scientific articles that have appeared during the previous week as well as abstracts accepted for presentation at the upcoming Society of Gynecologic Oncology (SGO) meeting in March.

This publications report includes links, when available, to the article, PubMed abstract, or association abstract.

ACCEPTED ABSTRACTS

Clements A, Enserro D, Previs RA, Matei D, Mutch DG, Powell MA, Klopp A, Miller DS, Small WC Jr., DiSilvestro P, Spirtos NM, Cosgrove C, Sfakianos G, Liu R, Vargas R, Shahin MS, Corr B, Van Le L, Ueland F, Warshal DP, Gillen J, Secord AA. Overall survival in patients in GOG-0258 by molecular classification with a modified promise algorythm: Ancillary analysis of GOG-258. SGO (Society of Gynecologic Oncology). 3/16/2024. LBA Oral Presentation.

Covens A, Huang H, Kim Y, Kim M, DiSilvestro PA, Vicus D, Holman L, Fleury AC, Pearson J, Thawani N, Shahin M, Lea J, Robertson SE, Warshal D, Backes F, Feltmate C, Dewdney S, Leitao M, Wilkinson-Ryan I, Elsayed A, Carter J. Evaluation Efficacy and Fertility After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy with Pelvic Lymphadenectomy) For Stage IA1 (LVSI+) and IA2-IB1 (GOG278). SGO (Society of Gynecologic Oncology). 3/16/2024. LBA Oral Presentation.

Covens A, Huang H, Kim Y, Kim M, Stuckey A, Vicus D, Holman LL, Fleury AC, Pearson J, Thawani N, Shahin MS, Lea J, Robertson SE, Warshal D, Backes F, Feltmate C, Wilkinson-Ryan I, Carter J. Evaluation of Physical Function and Quality of Life (Qol) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy with Pelvic Lymphadenectomy) For Stage IA1 (LVSI+) and IA2-IB1 (GOG#278). SGO (Society of Gynecologic Oncology). 3/16/2024. LBA Oral Presentation.

Eskander RN, Sill MW, Beffa L, Moore RG, Hope J, Musa FB, Mannel RS, Shahin MS, Cantuaria GH, Girda E, Mathews C, Kavecansky J, Leath CA III, Gien LT, Hinchclilff EM, Lele SB, Landrum LM, Backes F, O'Cearbhaill RE, Liu R, Hill EK, Thaker P, John VS, Powell MA, Aghajanian C. Overall Survival and Progression Free Survival by PD-L1 status in Endometrial Cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG GY018 trial. SGO (Society of Gynecologic Oncology). 3/16/2024. LBA Oral Presentation.

Eskander RN, Sill MW, Hagemann A, Waggoner S, Press JZ, Ghamande S, Bottsford-Miller J, Aghajanian C, Schram A. A phase II study of tazemetostat (EPZ-6438) in recurrent or persistent endometrioid or clear cell carcinoma of the ovary, and recurrent or persistent endometrioid endometrial adenocarcinoma. SGO (Society of Gynecologic Oncology). 3/16/2024. LBA Oral Presentation.

Lee J, Brady M, Miller A, Moore RG, MacKay H, McNally L, Lea JS, Street D, Lheureux S, Bender D, Duska LR, Cantuaria G, Kavecansky J, Leath CA III, Powell MA, Cadungog MG, Rose P, Bookman MA, Kohn EC, Secord A. A phase II/III study of cediranib and olaparib combination compared to cediranib or olaparib alone, or standard of care chemotherapy In platinum-resistant ovarian cancer (NRG-GY005). SGO (Society of Gynecologic Oncology). 3/16/2024. Plenary Oral Presentation.

PUBLISHED ARTICLES

Ganz PA, Bandos H, Spanic T, Friedman S, Muller V, Kummel S, Delaloge S, Brain E, Toi M, Yamauchi H, Eduardo-M De Duenas M, Armstrong A, Im S, Song C, Zheng H, Sarosiek T, Sharma P, Geng C, Fu P, Rhiem K, Frauchiger-Heuer H, Wimberger P, t'Kint de Roodenbeke D, Liao N, Goodwin A, Chakiba C, Friedlander M, Lee KS, Giacchetti S, Takano T, Henao Carrasco F, Virani S, Valdes-Albini F, Domchek S, Bane C, McCarron EC, Mita M, Rastogi P, Fielding A, Gelber RD, Scheepers E, Cameron D, Garber JE, Geyer CE Jr., Tutt AN. Patient-reported Outcomes in OlympiA: A Phase III, Multicenter, Randomized, Placebo-controlled Trial of Adjuvant Olaparib in Patients with gBRCA1/2 Mutations and High-risk HER2-negative Early Breast Cancer. J Clin Oncol. 2024 Feb 01. doi: 10.1200/JCO.23.01214. Epub ahead of print. Read More.

Polley MC, Schwartz D, Karrison T, Dignam JJ. Leveraging External Control Data in the Design and Analysis of Neuro-Oncology Trials: Pearls and Perils. Neuro Oncol. 2024 Jan 22:noae005. doi: 10.1093/neuonc/noae005. Epub ahead of print. PMID: 38254183. Read More.

Please note the following upcoming meetings and abstract submission deadlines

UPCOMING MEETINGS

American Association for Cancer Research (AACR); Apr 5-10, 2024; San Diego, CA

American Association for Thoracic Surgery (AATS); Apr 27-30, 2024; Toronto, ON

American College of Radiology (ACR); Apr 13-17, 2024; Washington, DC

American Head & Neck Society (AHNS); May 15-16, 2024; Chicago, IL

American Radium Society (ARS); May 2-5, 2024; Palm Springs, CA

American Society of Breast Surgeons (ABS); Apr 10-14, 2024; Orlando, FL

European Society of Gynaecological Oncology (ESGO); Mar 7-10, 2024; Barcelona, Spain

European Society for Radiotherapy and Oncology (ESTRO); May 3-7, 2024; Glasgow, Scotland

Society for Clinical Trials (SCT); May 19-22, 2024; Boston, MA

Society of Gynecologic Oncology (SGO); Mar 16-18, 2024; San Diego, CA

Society of Surgical Oncology (SSO); Mar 20-23, 2024; Atlanta, GA

Society of Surgical Oncology (SSO) - Advanced Cancer Therapies (ACT); Feb 16-19, 2024; San Juan, Puerto Rico



UPCOMING ABSTRACT SUBMISSIONS DEADLINES

American Brachytherapy Society (ABS) World Congress; Jul 10-13, 2024; National Harbor, MD; due to publications committee Feb 13, 2024; submission deadline Feb 27, 2024, 6:00 pm PT

American Society of Clinical Oncology (ASCO); May 31-Jun 4, 2024; Chicago, IL; submission deadline Feb 6, 2024, 11:59 pm ET; LBA Mar 11, 2024, 11:59 pm ET (placeholder required)

American Society of Colon and Rectal Surgeons (ASCRS); Jun 1-4, 2024; Baltimore, MD; submission deadline Feb 13, 2024, 11:59 pm PT

American Society for Radiation Oncology (ASTRO); Sep 29-Oct 2, 2024; Washington, DC; due to publications committee Feb 27, 2024; submission deadline Mar 12, 2024; LBA Jul 12, 2024

EORTC-NCI-AACR Symposium on Molecular Targets and therapies; Oct 23-25, 2024; Barcelona, Spain; due to publications committee Jun 13, 2024; submission deadline Jun 27, 2024; LBA Sep 26, 2024

European Society for Medical Oncology (ESMO); Sep 13-17, 2024; Barcelona, Spain; due to publications committee Apr 23, 2024; submission deadline May 7, 2024, 21:00 CET; LBA Aug 7, 2024, 21:00 CET (placeholder required)

European Society for Medical Oncology (ESMO) Breast Cancer; May 15-17, 2024; Berlin, Germany; submission deadline Feb 13, 2024, 21:00 CET; LBA Apr 17, 2024, 21:00 CET (placeholder required)

European Society for Medical Oncology (ESMO) Gastrointestinal; Jun 26-29, 2024; Munich, Germany; submission deadline Apr 9, 2024, 21:00 CET; LBA Jun 6, 2024, 21:00 CET (placeholder required)



European Society for Medical Oncology (ESMO) Gynaecological; Jun 20-22, 2024; Florence, Italy; due to publications committee Mar 20, 2024; submission deadline Apr 3, 2024, 21:00 CET (placeholder required)